Rayner Enters Canadian Ophthalmology Market
Following the recent approval of incorporation, Rayner announced that is will now be offering the Rayner portfolio of IOLs and injectors directly to Canadian surgeons. The entry into the Canadian market will be led by Wade Allen, Director: Americas, Rayner Surgical Corp.
The RayOne Aspheric fully preloaded monofocal IOL was recently approved for sale by Health Canada and Rayner is expecting imminent approval for the full range of RayOne fully preloaded IOLs, consisting of:
- RayOne EMV premium monofocal IOL
- RayOne Hydrophobic aspheric monofocal IOL
- RayOne Spheric monofocal IOL
- RayOne Toric IOL
- RayOne Trifocal IOL
- RayOne Trifocal Toric IOL
Rayner Surgical Corp said it already has a growing team of professional ophthalmic specialist territory managers dedicated exclusively to the Rayner portfolio in Canada. Through serving the Canadian cataract market directly, surgeons can expect new opportunities for training, feedback, and additional focus on unique platforms like RayPRO: a free contactless telehealth solution that collects 3 years’ worth of Patient Reported Outcomes (PROs) after cataract surgery. Rayner Surgical Corp will build a network of key opinion leaders (KOLs) within Canada, generating valuable collaborative partnerships and identifying new opportunities in IOL design and innovation.
“Rayner’s direct entry into Canada is an exciting development for Canadian ophthalmologists,” Dr. Davin Johnson, Queen’s University in Kingston, Ontario, said in a company news release. “Rayner offers an extensive diversity of high quality IOLs that is unparalleled in the degree of customization and extended range availability. I especially look forward to trialling Rayner’s line of presbyopia correcting IOLs in early 2021.”
With a 5-year plan to grow Rayner to over three times its current size, the strategy for moving to a direct-entry model in Canada is integral to achieving this goal, according to Rayner.
At 14.6 per thousand, Canada has the highest cataract surgery rate in the world,1 and the availability of Rayner’s complete range of fully preloaded lenses will give surgeons a full portfolio of options to improve visual outcomes for clinicians and patients.
“Our new Canadian business will enable us to not only serve Canadian surgeons better with our latest range of products, but it enables us to get closer to innovations and ideas generated in such an important market,” Rayner CEO, Tim Clover, said in the news release. “Wade Allen and Sam van Roon are a formidable team in North America and we look forward to growing our presence over the coming years.”
Rayner’s 2016 move to its global head office, R&D hub and large-scale manufacturing facility, will support their plans to expand their direct business on a global scale.
References
- Canada Market Scope Report 2019: p1.